Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

457
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
457
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

411
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
411
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

860
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
860
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.1K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.1K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

726
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
726
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

320
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
320

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delineating the potential of bioenergetics in drug discovery against Mycobacteriumabscessus.

Tuberculosis (Edinburgh, Scotland)·2026
Same author

Combination strategies targeting multiple ETC subunits as a rational approach for drug-resistant TB therapy.

Archives of microbiology·2026
Same author

Growth-dependent tRNA Reprogramming and Codon Bias Link Translation to Metabolic State in <i>Enterococcus faecalis</i>.

bioRxiv : the preprint server for biology·2026
Same author

Disrupting Biofilms and Enhancing Antibacterial Activity via Novel Ciprofloxacin-Lipid Conjugates.

Journal of medicinal chemistry·2026
Same author

<i>Enterococcus faecium</i> colonization and persistence in a model of diabetic wound infection.

Infection and immunity·2026
Same author

Simultaneous Inhibition of Cytochrome <i>bd</i> Oxidase and ATP Synthase for Complete Eradication of <i>Mycobacterium tuberculosis</i>.

ACS infectious diseases·2026

Related Experiment Video

Updated: Dec 15, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.9K

Toward a Single-Dose Cure for Buruli Ulcer.

Sangeeta S Thomas1,2, Nitin Pal Kalia2,3, Marie-Thérèse Ruf4,5

  • 1NTU Institute for Health Technologies (HealthTech NTU), Interdisciplinary Graduate Programme, Nanyang Technological University, Singapore.

Antimicrobial Agents and Chemotherapy
|July 8, 2020
PubMed
Summary
This summary is machine-generated.

A single dose of Q203 (Telacebec) successfully eradicated Mycobacterium ulcerans in mice, offering a promising new treatment for Buruli ulcer. This breakthrough could significantly simplify managing this neglected tropical disease.

Keywords:
Mycobacterium ulceransQ203Telacebecbedaquilinebioenergeticscytochrome bcc-aa3oxidative phosphorylationterminal oxidasetuberculosis

More Related Videos

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.3K
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.8K

Related Experiment Videos

Last Updated: Dec 15, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.9K
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.3K
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.8K

Area of Science:

  • Infectious Diseases
  • Mycobacterial Research
  • Drug Development

Background:

  • Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans.
  • Current treatment regimens for Buruli ulcer are lengthy and complex.
  • There is a need for simpler, more effective therapeutic options.

Purpose of the Study:

  • To evaluate the efficacy of Q203 (Telacebec) as a potential treatment for Buruli ulcer.
  • To assess the eradication of Mycobacterium ulcerans following a single dose of Q203.
  • To determine the long-term relapse rate after Q203 treatment in a preclinical model.

Main Methods:

  • A mouse model of Buruli ulcer infection was utilized.
  • Mice received a single dose of Q203 (Telacebec).
  • Efficacy was assessed by monitoring bacterial eradication and relapse up to 19 weeks posttreatment.

Main Results:

  • A single dose of Q203 demonstrated complete eradication of Mycobacterium ulcerans.
  • No relapse of infection was observed up to 19 weeks after treatment.
  • Q203 proved highly effective in the preclinical model of Buruli ulcer.

Conclusions:

  • Q203 (Telacebec) is a highly promising candidate for Buruli ulcer treatment.
  • A single-dose regimen could revolutionize clinical management of this neglected disease.
  • Further clinical development of Q203 is warranted to confirm these findings in humans.